Impact on Colorectal Cancer Mortality of Screening Programmes Based on the Faecal Immunochemical Test
Overview
Authors
Affiliations
Objective: Colorectal cancer (CRC) screening programmes based on the guaiac faecal occult blood test (gFOBT) reduce CRC-specific mortality. Several studies have shown higher sensitivity with the faecal immunochemical test (FIT) compared with gFOBT. We carried out an ecological study to evaluate the impact of FIT-based screening programmes on CRC mortality.
Design: In the Veneto Region (Italy), biennial FIT-based screening programmes that invited 50-69-year-old residents were introduced in different areas between 2002 and 2009. We compared CRC mortality rates from 1995 to 2011 between the areas where screening started in 2002-2004 (early screening areas (ESA)) and areas that introduced the screening in 2008-2009 (late screening areas (LSA)) using Poisson regression models. We also compared available data on CRC incidence rates (1995-2007) and surgical resection rates (2001-2012).
Results: Before the introduction of screening, CRC mortality and incidence rates in the two areas were similar. Compared with 1995-2000, 2006-2011 mortality rates were 22% lower in the ESA than in the LSA (rate ratio (RR)=0.78; 95% CI 0.68 to 0.89). The reduction was larger in women (RR=0.64; CI 0.51 to 0.80) than in men (RR=0.87; CI 0.73 to 1.04). In the ESA, incidence and surgery rates peaked during the introduction of the screening programme and then returned to the baseline (2006-2007 incidence) or dropped below initial values (surgery after 2007).
Conclusions: FIT-based screening programmes were associated with a significant reduction in CRC mortality. This effect took place much earlier than reported by gFOBT-based trials and observational studies.
Arasaradnam R, Krishnamoorthy A, Hull M, Wheatstone P, Kvasnik F, Persaud K Sensors (Basel). 2025; 25(3).
PMID: 39943238 PMC: 11820771. DOI: 10.3390/s25030599.
Risk factors, prevention and screening of colorectal cancer: A rising problem.
Tsukanov V, Vasyutin A, Tonkikh J World J Gastroenterol. 2025; 31(5):98629.
PMID: 39926213 PMC: 11718609. DOI: 10.3748/wjg.v31.i5.98629.
Lee H, Lee K, Kim B, Jun J, Choi K, Suh M Cancers (Basel). 2025; 16(24.
PMID: 39766178 PMC: 11674503. DOI: 10.3390/cancers16244278.
Opperman R, Bosch S, Nazmi K, Bikker F, Brand H, Jimenez C Anal Chem. 2024; 96(51):20239-20246.
PMID: 39665576 PMC: 11672227. DOI: 10.1021/acs.analchem.4c04586.
Cao Q, Dan Z, Hou N, Yan L, Yuan X, Lu H Clin Epigenetics. 2024; 16(1):122.
PMID: 39244604 PMC: 11380779. DOI: 10.1186/s13148-024-01735-6.